After layoffs leave Oncorus a 'shell' of a company, board liquidates the business

A week after Oncorus shed pretty much all its staff, the biotech’s board has decided that the game is up and moved to liquidate the RNA-focused company.

The 55 layoffs announced June 1, which included virtually the entire C-suite, left Oncorus’ fate hanging in the balance, with the company feeling out “all available strategic options” to ward off an “orderly wind down.”